Spero Therapeutics, Inc. (SPRO) News
Filter SPRO News Items
SPRO News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SPRO News Highlights
- For SPRO, its 30 day story count is now at 6.
- Over the past 25 days, the trend for SPRO's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about SPRO are DRUG and RARE.
Latest SPRO News From Around the Web
Below are the latest news stories about SPERO THERAPEUTICS INC that investors may wish to consider to help them evaluate SPRO as an investment opportunity.
Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics IncOn September 13, 2023, Chief Medical Officer Kamal Hamed sold 39,496 shares of Spero Therapeutics Inc (NASDAQ:SPRO). |
Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of DirectorsBOSTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Sensorium Therapeutics (Sensorium), a biotechnology company translating insights from nature and human experience to deliver transformational therapeutics, today announced the appointment of veteran life sciences executive David Southwell to its Board of Directors. “We are excited to welcome David to our Board,” said Dick Simon, Chief Executive Officer of Sensorium. “He is a seasoned life sciences executive with a track record of success that spans mult |
Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment ConferenceCAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Sath Shukla, President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the H.C. Wainwright 25 |
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Aug. 31, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas involving rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that on August 25, 2023, the Compensation Committee of Spero’s Board of Directors approved the grant of an aggregate of 83,000 restricted stock unit awards (RSUs) to t |
Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock?Spero Therapeutics, Inc. (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a TurnaroundThe heavy selling pressure might have exhausted for Spero Therapeutics, Inc. (SPRO) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal. |
Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call TranscriptSpero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript August 10, 2023 Spero Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.23, expectations were $-0.29. Operator: Good afternoon and welcome to the Spero Therapeutics Second Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call is being recorded and a replay […] |
Q2 2023 Spero Therapeutics Inc Earnings CallQ2 2023 Spero Therapeutics Inc Earnings Call |
Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue EstimatesSpero Therapeutics, Inc. (SPRO) delivered earnings and revenue surprises of 20.69% and 23.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock? |
Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business UpdateSPA Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr Phase 3 PIVOT-PO trial is expected to begin with First Patient, First Visit in 4Q 2023 Sath Shukla Became President and CEO, Effective August 1 Conference call and webcast at 4:30pm ET today CAMBRIDGE, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying, developing and commercializing treatments in high unmet need areas in |